Johnson & Johnson’s HIV Vaccine Fails To Show Promising Results In Mid-Stage Africa Study

By John F. Heerdink, Jr.

As per reports, Johnson & Johnson (JNJ) experimental vaccine failed to provide sufficient protection against HIV in sub-Saharan Africa to young women who accounted for a large number of infections last year. Results from the mid-stage study are the latest setback to efforts to develop a vaccine to prevent HIV or human immunodeficiency virus, causing AIDS.

“Although this is certainly not the study outcome for which we had hoped, we must apply the knowledge learned from the trial and continue our efforts to find a vaccine that will be protective against HIV,” stated Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases (NIAID).

There are effective treatments that can put the virus in remission, however, experts believe an HIV vaccine is critical to eradicating the virus. The mid-stage J&J study testing included 2,600 women participants across five Southern African countries, where over 60% of women and girls accounted for all new HIV infections last year. Researchers found that 63 participants who received a placebo and 51 who were administered the J&J vaccine got HIV infection, resulting in a vaccine efficacy of 25.2%. Johnson & Johnson informed that the vaccine had no serious side effects and was safe, but the study will not continue based on the efficacy data. The vaccine trial was supported by the NIAID and the Bill & Melinda Gates Foundation.

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.